Related Experiment Video
Updated: Nov 7, 2025
03:52
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
693
Adiponectin and Sarcopenia: A Systematic Review With Meta-Analysis.
Klara Komici1, Antonio Dello Iacono2, Antonio De Luca3
1Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.
Frontiers in Endocrinology
|May 3, 2021
Summary
Sarcopenia, a loss of muscle mass, is linked to higher adiponectin levels. This systematic review and meta-analysis suggests a connection, but further research is needed to confirm the association between adiponectin and sarcopenia.
Area of Science:
- Gerontology
- Metabolism
- Inflammation
Background:
- Sarcopenia is characterized by progressive skeletal muscle mass loss.
- Pathophysiology may involve inflammatory and endocrine factors.
- Adiponectin influences inflammation and muscle metabolism, but its role in sarcopenia is unclear.
Purpose of the Study:
- To systematically review and meta-analyze existing evidence on serum adiponectin levels in sarcopenic individuals compared to controls.
Main Methods:
- A comprehensive electronic literature search was conducted across major databases (Medline/PubMed, Cochrane Library, Science Direct) up to March 1, 2020.
- Meta-analysis of cross-sectional studies compared serum adiponectin levels between sarcopenic patients and non-sarcopenic controls.
Main Results:
- Seven studies were included in the meta-analysis.
- Sarcopenic participants exhibited significantly higher serum adiponectin levels (Hedges' g = 1.20, p = 0.02).
- Subgroup analyses in Asian populations (AWGS criteria) and meta-regression indicated female gender influences the association.
Conclusions:
- The meta-analysis provides evidence for an association between sarcopenia and elevated adiponectin levels.
- Caution is advised in interpreting these findings.
- Future longitudinal studies are necessary to elucidate the relationship.
Related Concept Videos
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
43
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
43
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
44
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
44
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
60
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
60
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
65
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
65
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
59
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
59